Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Characterization of a novel Helicobacter pylori East Asian-type CagA ELISA for detecting patients infected with various cagA genotypes.

Doohan D, Miftahussurur M, Matsuo Y, Kido Y, Akada J, Matsuhisa T, Yee TT, Htet K, Aftab H, Vilaichone RK, Mahachai V, Ratanachu-Ek T, Tshering L, Waskito LA, Fauzia KA, Uchida T, Syam AF, Rezkitha YAA, Yamaoka Y.

Med Microbiol Immunol. 2020 Feb;209(1):29-40. doi: 10.1007/s00430-019-00634-5. Epub 2019 Sep 23.

PMID:
31549252
2.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

3.

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.

Batty P, Austin SK, Khair K, Millar CM, Palmer B, Rangarajan S, Stümpel JP, Thanigaikumar M, Yee TT, Hart DP.

Br J Haematol. 2017 Mar;176(5):796-804. doi: 10.1111/bjh.14543. Epub 2017 Feb 15.

4.

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.

van Velzen AS, Eckhardt CL, Streefkerk N, Peters M, Hart DP, Hamulyak K, Klamroth R, Meijer K, Nijziel M, Schinco P, Yee TT, van der Bom JG, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2016 Mar;115(3):543-50. doi: 10.1160/TH15-03-0212. Epub 2015 Nov 19.

PMID:
26582077
5.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.

van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2015 Jul;114(1):46-55. doi: 10.1160/TH14-11-0940. Epub 2015 Apr 16.

PMID:
25879247
6.

The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease.

Makris M, Federici AB, Mannucci PM, Bolton-Maggs PH, Yee TT, Abshire T, Berntorp E.

Haemophilia. 2015 May;21(3):338-42. doi: 10.1111/hae.12571. Epub 2014 Nov 7.

PMID:
25381842
7.

Proteomic characterization and comparison of Malaysian Bungarus candidus and Bungarus fasciatus venoms.

Rusmili MR, Yee TT, Mustafa MR, Hodgson WC, Othman I.

J Proteomics. 2014 Oct 14;110:129-44. doi: 10.1016/j.jprot.2014.08.001. Epub 2014 Aug 19.

PMID:
25154052
8.

Isolation and characterization of a presynaptic neurotoxin, P-elapitoxin-Bf1a from Malaysian Bungarus fasciatus venom.

Rusmili MR, Yee TT, Mustafa MR, Hodgson WC, Othman I.

Biochem Pharmacol. 2014 Oct 1;91(3):409-16. doi: 10.1016/j.bcp.2014.07.001. Epub 2014 Jul 23.

PMID:
25064255
9.

In-vitro neurotoxicity of two Malaysian krait species (Bungarus candidus and Bungarus fasciatus) venoms: neutralization by monovalent and polyvalent antivenoms from Thailand.

Rusmili MR, Yee TT, Mustafa MR, Othman I, Hodgson WC.

Toxins (Basel). 2014 Mar 12;6(3):1036-48. doi: 10.3390/toxins6031036.

10.

Guidance on the dental management of patients with haemophilia and congenital bleeding disorders.

Anderson JA, Brewer A, Creagh D, Hook S, Mainwaring J, McKernan A, Yee TT, Yeung CA.

Br Dent J. 2013 Nov;215(10):497-504. doi: 10.1038/sj.bdj.2013.1097.

PMID:
24264665
11.

Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.

Fransen van de Putte DE, Makris M, Fischer K, Yee TT, Kirk L, van Erpecum KJ, Patch D, Posthouwer D, Mauser-Bunschoten EP.

J Hepatol. 2014 Jan;60(1):39-45. doi: 10.1016/j.jhep.2013.08.010. Epub 2013 Aug 23.

PMID:
23978717
12.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.

Blood. 2013 Sep 12;122(11):1954-62. doi: 10.1182/blood-2013-02-483263. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

PMID:
23926300
13.

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM; rVWF Ad Hoc Study Group.

Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18.

14.

Update to UKHCDO guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease.

Watson HG, Wilde JT, Dolan G, Millar C, Yee TT, Makris M; Morbidity and Mortality Working Party UKHCDO.

Haemophilia. 2013 May;19(3):e191-2. doi: 10.1111/hae.12139. No abstract available.

PMID:
23600911
15.

Intestinal inflammatory pseudotumor caused by taeniasis: Calcareous corpuscles as a diagnostic clue.

Khin SS, Kitazawa R, Htet K, Htike HM, Yee TT, Aung M, Haraguchi R, Kitazawa S.

Pathol Int. 2013 Mar;63(3):193-4. doi: 10.1111/pin.12046. No abstract available.

PMID:
23530565
16.

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PH, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

Hum Mol Genet. 2013 May 1;22(9):1903-10. doi: 10.1093/hmg/ddt033. Epub 2013 Jan 30.

17.

SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.

Négrier C, Lienhart A, Numerof R, Stephens D, Wong WY, Baghaei F, Yee TT.

Haemophilia. 2013 May;19(3):e143-50. doi: 10.1111/hae.12080. Epub 2013 Jan 3.

PMID:
23282031
18.

Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.

Rangarajan S, Austin S, Goddard NJ, Négrier C, Rodriguez-Merchan EC, Stephensen D, Yee TT.

Haemophilia. 2013 Mar;19(2):294-303. doi: 10.1111/hae.12028. Epub 2012 Sep 19. Review.

PMID:
22989234
19.

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.

Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE, Lemm G.

J Thromb Haemost. 2012 May;10(5):773-80. doi: 10.1111/j.1538-7836.2012.04667.x.

20.

Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world.

Sørensen B, Benson GM, Bladen M, Classey S, Keeling DM, McLaughlin P, Yee TT, Makris M.

Haemophilia. 2012 Jul;18(4):598-606. doi: 10.1111/j.1365-2516.2011.02720.x. Epub 2011 Dec 12.

PMID:
22151135
21.

UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011.

Wilde JT, Mutimer D, Dolan G, Millar C, Watson HG, Yee TT, Makris M.

Haemophilia. 2011 Sep;17(5):e877-83. doi: 10.1111/j.1365-2516.2011.02585.x. Epub 2011 Jun 9. Review.

PMID:
21658165
22.

Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.

Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT.

Haemophilia. 2012 Jan;18(1):46-9. doi: 10.1111/j.1365-2516.2011.02552.x. Epub 2011 May 5.

PMID:
21545378
23.

Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors.

Rangarajan S, Yee TT, Wilde J.

Haemophilia. 2011 Jan;17(1):28-34. doi: 10.1111/j.1365-2516.2010.02360.x.

PMID:
20642787
24.

FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.

Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M, Lassila R, Mumford A, Pasi J, Wilde J, Will A, Yee TT.

Haemophilia. 2010 Jan;16(1):80-9. doi: 10.1111/j.1365-2516.2009.02104.x. Epub 2009 Sep 23.

PMID:
19780845
25.

Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study.

Posthouwer D, Yee TT, Makris M, Fischer K, Griffioen A, Van Veen JJ, Mauser-Bunschoten EP.

J Thromb Haemost. 2007 Aug;5(8):1624-9.

26.

Acquired haemophilia masked by warfarin therapy.

Vadikolia CM, Riddell A, Brooks S, Yee TT, Brown S, Lee C.

Int J Lab Hematol. 2007 Feb;29(1):64-8.

PMID:
17224010
27.

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study.

Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, van Erpecum KJ, Mauser-Bunschoten EP.

Blood. 2007 May 1;109(9):3667-71. Epub 2007 Jan 9.

PMID:
17213288
28.

Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient.

Killingley B, Bhagani S, Slapak G, Yee TT, Johnson M.

Haemophilia. 2006 Sep;12(5):545-7.

PMID:
16919087
29.

Transfusion-transmitted infection in hemophilia in developing countries.

Yee TT, Lee CA.

Semin Thromb Hemost. 2005 Nov;31(5):527-37. Review.

PMID:
16276461
30.

Twenty five years of HIV infection in haemophilic men in Britain: an observational study.

Sabin CA, Phillips AN, Yee TT, Griffioen A, Lee CA.

BMJ. 2005 Oct 29;331(7523):997-8. Epub 2005 Sep 16. No abstract available.

31.

Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens.

Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, Chang HH, Kim SW, Lee H, Kim YS, Oh WS, Peck KR, Chongthaleong A, Lalitha MK, Perera J, Yee TT, Jamal F, Kamarulzaman A, Carlos CC, So T; Asian Network for Surveillance of Resistant Pathogens Study Group.

Clin Infect Dis. 2004 Jun 1;38(11):1570-8. Epub 2004 May 13.

PMID:
15156445
32.

High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).

Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, Ki HK, Oh WS, Suh JY, Peck KR, Lee NY, Yang Y, Lu Q, Chongthaleong A, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumarasinghe G, Jamal F, Kamarulzaman A, Parasakthi N, Van PH, Carlos C, So T, Ng TK, Shibl A.

Antimicrob Agents Chemother. 2004 Jun;48(6):2101-7.

33.

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae from Asian countries: ANSORP study.

Oh WS, Suh JY, Song JH, Ko KS, Jung SI, Peck KR, Lee NY, Yang Y, Chongthaleong A, Chiu CH, Kamarulzaman A, Parasakthi N, Lalitha MK, Perera J, Yee TT, Kumarasinghe G, Carlos CC; ANSORP Study Group.

Microb Drug Resist. 2004 Spring;10(1):37-42.

PMID:
15140392
34.

Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP).

Song JH, Chang HH, Suh JY, Ko KS, Jung SI, Oh WS, Peck KR, Lee NY, Yang Y, Chongthaleong A, Aswapokee N, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumararasinghe G, Jamal F, Kamarulazaman A, Parasakthi N, Van PH, So T, Ng TK; ANSORP Study Group.

J Antimicrob Chemother. 2004 Mar;53(3):457-63. Epub 2004 Feb 12.

PMID:
14963068
35.

Comparative study of full-length and B-domain deleted factor VIII concentrates.

Brown SA, Yee TT, Griffioen A, Lee CA.

Haemophilia. 2003 Nov;9(6):745; author reply 748-50. No abstract available.

PMID:
14750944
36.

Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study.

Sabin CA, Griffioen A, Yee TT, Emery VC, Herrero-Martinez E, Phillips AN, Lee CA.

Lancet. 2002 Nov 16;360(9345):1546-51.

PMID:
12443592
37.

Long-term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders.

Sabin CA, Emery V, Devereux HL, Griffioen A, Bishop J, Dusheiko G, Yee TT, Herrero-Martinez E, Lee CA.

J Med Virol. 2002 Sep;68(1):68-75.

PMID:
12210432
38.

Experience of prophylaxis treatment in children with severe haemophilia.

Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, Lee CA, Brown SA.

Haemophilia. 2002 Mar;8(2):76-82.

PMID:
11952841
39.

Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII.

van den Brink EN, Bril WS, Turenhout EA, Zuurveld M, Bovenschen N, Peters M, Yee TT, Mertens K, Lewis DA, Ortel TL, Lollar P, Scandella D, Voorberg J.

Blood. 2002 Apr 15;99(8):2828-34.

PMID:
11929772
40.

Multiple myeloma and human immunodeficiency virus-1 (HIV-1) infection.

Yee TT, Murphy K, Johnson M, Abdalla SH, Patton GS, Lee CA, Mehta AB.

Am J Hematol. 2001 Feb;66(2):123-5.

41.

Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP).

Lee NY, Song JH, Kim S, Peck KR, Ahn KM, Lee SI, Yang Y, Li J, Chongthaleong A, Tiengrim S, Aswapokee N, Lin TY, Wu JL, Chiu CH, Lalitha MK, Thomas K, Cherian T, Perera J, Yee TT, Jamal F, Warsa UC, Van PH, Carlos CC, Shibl AM, Jacobs MR, Appelbaum PC.

Clin Infect Dis. 2001 May 15;32(10):1463-9. Epub 2001 Apr 20.

PMID:
11317248
42.

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.

Yee TT, Taher A, Pasi KJ, Lee CA.

Clin Lab Haematol. 2000 Oct;22(5):275-8.

PMID:
11122268
43.

The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985.

Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA.

Gut. 2000 Dec;47(6):845-51.

44.

Oral immune tolerance induction to factor VIII via breast milk, a possibility?

Yee TT, Lee CA.

Haemophilia. 2000 Sep;6(5):591. No abstract available.

PMID:
11012709
45.

Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.

Sabin CA, Yee TT, Devereux H, Griffioen A, Loveday C, Phillips AN, Lee CA.

AIDS. 2000 May 26;14(8):1001-7.

PMID:
10853982
46.

Family issues in HIV-infected haemophilic patients.

Yee TT, Goldman E, Devereux H, Sabin C, Lee CA.

AIDS. 1999 Nov 12;13(16):2314-5. No abstract available.

PMID:
10563724
47.

Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study.

Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, Fu W, Chongthaleong A, Aswapokee N, Chiu CH, Lalitha MK, Thomas K, Perera J, Yee TT, Jamal F, Warsa UC, Vinh BX, Jacobs MR, Appelbaum PC, Pai CH.

Clin Infect Dis. 1999 Jun;28(6):1206-11.

PMID:
10451154
48.

Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?

Yee TT, Lee CA.

Thromb Haemost. 1999 May;81(5):852. No abstract available.

PMID:
10365768
49.

Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97.

Yee TT, Pasi KJ, Lilley PA, Lee CA.

Br J Haematol. 1999 Mar;104(4):909-14.

PMID:
10192458
50.

Supplemental Content

Support Center